Sponsored by
This small study was in patients with glioblastoma multiforme who failed Temodar and Avastin. In general, patients who failed these 2 treatments live an average of an additional 2 months without further treatment, or 5.2 months with salvage therapies. With high dose Val-083, median survival was 9.2 more with 1/3 of the patients being alive at the 12 month point. Pretty good results in a very bad patient population.
Phase I/II Study of Dianhydrogalactitol in Patients with Recurrent Malignant Glioma